having respiratory symptoms might be misdiagnosed due to atypical case presentation, insufficient etiological investigation or overlapping of diseases. Although asthma and COPD have distinct characteristics, both cause chronic inflammation of the airways and have certain risk factors which are common. Thus, comprehensive assessments should be conducted concerning any risk factors or exposure, time of onset and severity of the presenting exacerbation and of previous exacerbation episodes, medication use, comorbidities, prior hospitalizations, history of respiratory failure, and other information in the course of a differential diagnosis. Briefly, the assessment of asthma and COPD is required to determine the severity of the disease, its impact on health status and the risk of future events (e.g. exacerbations, hospital admissions or death) and is essential to guide therapy. When the clinical history of a patient who is suspected to have or is at high risk for obstructive airway disease is being taken, a proactive approach is warranted.
Compliance to treatment is still a major problem in all chronic diseases. Compliance to pharmacological treatment in asthma and COPD, in particular, is known to be low. Increase in exacerbations and hospitalization rate in asthma patients could be associated with poor compliance to treatment. In several studies the clinician-and patient-related causes of poor compliance to treatment in asthma/COPD patients have been evaluated (5, 6) . Şen et al. also studies this issue in Turkish population (7) . Thus, this study was designed to evaluate the physician-, patient-and environment-related aspects of compliance to treatment in newly diagnosed treatment-naïve asthma/ COPD patients to reveal the current status in Turkey. As it is the first nationwide study on this area in real life, we believe that our findings will have a beneficial impact on asthma/COPD patients' health and healthcare costs.
MATeRIALs and MeTHods study design
This study is a national, multicentre, prospective and non-interventional study focused on the diagnosis and treatment approaches under real life conditions, aiming to observe the natural progression of asthma and COPD. The study protocol was approved by the Erciyes University Faculty of Medicine Ethics Committee (February 10, 2012) . The study was conducted between June 2012 and March 2014.
Patients were enrolled based on GINA (Global Initiative for Asthma) 2012 for asthma and GOLD (Global Initiative for COPD) 2011 for COPD (8, 9) . A standard web-based questionnaire including items related to demographic, clinical, laboratory and treatment parameters was applied to patients. All procedures were administered by the investigators at 122 centres, and supervised by the Executive Board consisting of 11 asthma/COPD specialists with the help of an authorized contract research organization.
Patients
To select the study patients and to avoid bias, the physicians screened all patients consecutively and all eligible patients were informed about the study. Asthma/COPD patients meeting the inclusion criteria below were included in the study:
• Age of diagnose: ≥ 18 -≤ 80 years for asthma and ≥ 40 -≤ 80 years for COPD patients.
• Diagnosis of asthma/COPD in the previous three months at latest or after the initiation visit.
• Patients who have not taken asthma/COPD maintenance treatment except short-acting beta agonists.
• Diagnosis of asthma/COPD which was validated via respiratory function tests.
• Patients (or their legal representatives) who accepted to sign the informed consent form.
Procedures and Measures
A "Case Report Form" was prepared by the Executive Board and contract research organization. Data included the information written on patient's routine medical records. Previous and current medical history data collected at the initiation visit included: the referral information; demographics (the region of life spent longest, the region of life spent in last three months, height, body weight, body mass index and education status); aetiology; medical history (reasons of application, concomitant diseases, family history); risk factors (smoking, occupation, trigger factors, heating and cooking methods); diagnostic tests (including spirometry); disease severity (GINA severity table for asthma and GOLD criteria for COPD); asthma phenotype; and treatment.
After the initial visit, all patients were followed-up for 12 months. Intended timing for the visits were 0-1 month for visit-1, 1-3 months for visit-2 and 3-12 months for visit-3, however, the frequency of the visits was not determined by the study protocol; physicians were completely free to plan the follow-up procedures. Data on disease progression and outcome collected during the follow-up visits included the information on admission (reason for admission, hospitalization, signs and symptoms), assessment of disease control (asthma control test for asthma and GOLD assessment for COPD), assessment of compliance to treatment, and spirometric examination if needed by the physician. Compliance of the patients' to medication was evaluated by the physician at each visit using a scale. According to this scale, "high compliance" defines the patients who use medications regularly, "medium compliance" and "low compliance" terms define those who use medications with partial or severe interruptions, respectively. And finally, "noncompliance" defines the patients who did not use medication.
data Management
Physicians were blind to patients of other centres. All lower/upper limits regarding the laboratory test results, decimals, birth dates, etc. were identified in the software and entries out of limits were not allowed. System retrieved and weekly updated the package information (name, dosage, pharmaceutical form) of all the medications from the list at the web site of Turkish Drug and Medical Device Institution (www. iegm.gov.tr) and allowed physicians to choose the correct and valid name of medication.
To improve data quality, the audit visits were performed at 20 centres (15% of all) which included 450 patients (22% of all) and data were compared with the source documents. Data were protected at high capacity servers located at data centre of Türk Telekom (communication and substructure provider company). System equipments were designed binary so as to provide back-up in case of any breakdown. Security of the system was provided with software like firewall, antivirus, antispam, IPS (Intrusion Prevention System) and VPN (Virtual Private Network). SSL/VPN (Secure Socket Layer/Virtual Private Network) technology was used for encryption of data base. To ensure the secure data transfer, a "https://" (Hyper Text Transfer Protocol Secure) link was used.
statistical Analysis
The primary objective of the study was to determine the physicians' approach towards asthma/COPD patients. Sample size calculation was based on to detect the frequency of least common approach (which was set at "used in at least 5% of the patients") within ± %1 error and 95% confidence interval. With these assumptions, the number of patients to be enrolled was calculated as 1817.
Patients' demographics and disease characteristics were presented with descriptive statistics. Group comparisons were performed using chi-square test and Student's t test. For the comparison of numeric variables among more than two groups, one-way variance analysis (ANOVA) followed by Tukey HSD test was used. For the comparison of proportions in conditions with low number of cases, Fisher chisquare test and for the comparison of ordinal proportions, Mantel-Haenszel chi-square test was used. 
ResuLTs
A total of 1892 newly diagnosed treatment-naïve adult patients (1116 with asthma and 776 with COPD) from 122 centres were included in the analysis. 45.0% of the asthma patients had moderate and 37.0% had mild persistent asthma. Among COPD patients, 39.2% had stage B and 28.5% had stage C disease severity according to GOLD criteria ( Table 2) . 53.9% of asthma and 52.8% of COPD patients had comorbidities. The most frequently observed comorbidities are the upper respiratory system disorders, hypertension, and gastroesophageal reflux in asthma, and hypertension, coronary artery disease and diabetes mellitus in COPD (Table 2) . Table 3 and Figure 1 show the adherence of the physicians to clinical guidelines in terms of medications used by the patients with different disease severity stages. According to the analysis, the majority of the asthma patients with intermittent, mild persistent and moderate persistent disease severity are over-treated, i.e. treated more aggressively than recommended in the clinical practice guidelines (95%, 86% and 65%, respectively). Among COPD patients, the percentages of over-treated patients are 66%, 79% and 82% for those with GOLD stage A, B and C, respectively. The adherence level of the physicians to guidelines seems to be appropriate in 93% of the asthma patients with severe persistent disease severity and 89% of the COPD patients with GOLD stage D. Figure 2 demonstrates the disease control level of the asthma patients with different levels of compliance to treatment during the follow-up period. Among those with high treatment compliance at visit-1, 44% were totally controlled. Total control rate improved and reached to 52% at visit-2 and to 63% at visit-3. Among those with high treatment compliance, the percentage of patients with uncontrolled disease was only 5% in all three visits.
Follow-up of the Patients
In a similar fashion, among COPD patients with high treatment compliance, 41% had GOLD stage A disease severity at visit-1. This level was 54% at visit-2 and 50% at visit-3. During the follow-up, the 1 . Adherence to recommendations of clinical guidelines regarding medication use in patients with asthma/chronic obstructive pulmonary disease (COPD) in different disease severity classes and stages. The disease severity groups show statistically significant differences in terms of adherence to guidelines in both patient groups (p< 0.001).
percentage of patients with GOLD stage B and C disease severity showed a gradual decrease.
dIscussIoN
The present multi-centre, non-interventional study demonstrates the data related to real life practice and outcomes of Turkish asthma/COPD patients by examining their clinical and demographical characteristics. The major purpose of the study was to wwcompare the disease characteristics among newly diagnosed treatment-naïve patient groups. In addition to this, the study also evaluated medication preferences of the physicians in real life practice. Our disease severity data revealed that 53.5% of the asthma patients had moderate persistent or severe persistent asthma and 35.1% of COPD patients had GOLD stage C or D disease severity. Thus, one of the important findings of our study was that both asthma and COPD patients had a considerable high disease severity at the time of diagnosis. This might be explained by the fact that they are underdiagnosed at the onset of the disease. It may also be the result of a delay in Figure 2 . The disease control level of asthma patients and disease severity of chronic obstructive pulmonary disease (COPD) patients with different levels of treatment compliance during the follow-up. For asthma patients, the disease control levels show statistically significant differences among groups with different compliance to treatment levels in all three visits (p< 0.001). For COPD patients, the disease severity levels show statistically significant differences among groups with different compliance to treatment levels at all three visits (p= 0.038, at visit-1; p< 0.001, at visit-2, and p=0.010, at visit-3).
consulting a physician. The slowly progressive nature of COPD means that the disease usually remains undetected for many years, and most patients are first identified when they present with an exacerbation. Often, recognition of COPD does not occur until the disease has progressed to moderate or severe stages, by which time patients' symptoms have worsened (10) . By the time COPD is diagnosed at a later stage of disease when the need for healthcare utilisation is high (11) .
A previous study conducted in Turkey demonstrated that COPD patients are not diagnosed in early stage (12) . It is also important to recognize that patients may display a lack of awareness of the disease. Failing to identify symptoms at the start of the disease, accepting breathlessness and reduced exercise tolerance as part of normal aging, or attributing cough and sputum to their smoking habit are the common attitudes in COPD patients. A study which was designed and performed as a Global Alliance Against Respiratory Disorders (GARD) project including 8342 people showed that awareness of asthma/COPD is insufficient among Turkish people (13) . Thus, the implementation of appropriate education programs for both patients and physicians aiming to improve strategies for disease management and to increase the patients' compliance to visits might be considered.
Although management approaches and goals for asthma and COPD differ, both involve lifestyle modification concomitant with pharmacotherapy. As smoking is known to accelerate loss of lung function, smoking cessation is a high priority in COPD patients. Active smoking is also a critical factor in the risk of poor asthma control (14) (15) (16) . Thus, lifestyle modification begins with smoking cessation, regardless of the diagnosis. In a previous study by Günen et al. the smoking rate and COPD prevalence were found to be unexpectedly high in Malatya region of Turkey (17) . In our study, 56% of COPD and 28% of asthma patients are active smokers. In the clinical practice, active smokers with dyspnoea are frequently diagnosed with COPD. However, many recent papers have reported that cigarette smoking is surprisingly frequent in asthma patients, with a prevalence that is relatively close to that found in the general population (18) (19) (20) . Our data revealing the high percentage of active smokers among asthma patients imply that asthma should also be considered for these patients in differential diagnosis. In addition to this, second-hand smoke is a particular problem for people with asthma, as it directly triggers asthma episodes and increases airway responsiveness to irritants and allergens (21) . As the most common trigger factor is air pollution in our study (65.4% and 60.7% for asthma and COPD, respectively), efforts to control environmental air pollution are also essential to help minimizing the exacerbation risk especially in asthma patients (22) .
In this study, we also evaluated whether the physicians follow the medication recommendations described in the guidelines for their patients or not. Although it might be speculated that the clinical practice of the physicians may show variations, our study was conducted by 11 asthma/COPD specialists from various hospitals (9 university hospitals, 1 state hospital and 1 private hospital) from different geographic regions selected from a list of institutions to represent the whole country. Our analysis demonstrated that the majority of asthma patients with intermittent, mild persistent and moderate persistent disease severity and COPD patients with GOLD stage A, B and C disease severity is over-treated. The adherence level of the physicians to guidelines seems to be appropriate in 93% of the asthma patients with severe persistent disease severity and 89% of the COPD patients with GOLD stage D. Thus, these findings imply that the clinicians may not follow the medication algorithm described in the guidelines at all times. On the other hand, the current studies show that low adherence to GINA and GOLD guideline recommendations has been reported worldwide (7, 23, 24) . One possible explanation physicians' preference for a more aggressive treatment than usual would be that patients delay to visit a physician in the early phase of the disease; thus, they require a more aggressive treatment than usual at the time of their visit. The other possible explanation might be that the physicians consider the patients' risk factors while prescribing the medication. This is in line with our data showing a considerably high level of smoking and obesity in patients. Thus, in addition to implementing strategies to raise patient awareness, implementing education programs for physicians to update their level of knowledge would be effective interventions which would otherwise lead to a substantial increase in the economic burden of the disease in long-term basis.
Effective disease management of asthma/COPD includes a proper diagnosis, environmental control and control of adherence. Follow-up visits should include checking adherence/compliance to the medication plan and recommendations for reducing exposure to risk factors and should take place at regular intervals. Adherence rates in asthma and COPD are known to vary from 22% to 78% (25) (26) (27) . Although treatment success in asthma and COPD is largely dependent upon medication adherence, suboptimal disease management, including the failure of physicians to adhere to treatment guidelines, also plays a part (28) . Good adherence is associated with reduced exacerbation rates in patients with asthma and COPD (29) (30) (31) . A subgroup analysis of the TORCH (Towards a Revolution in COPD Health) study showed that good compliance to study medication in patients with COPD was associated with lower mortality rates compared with poor compliance (11.3% vs. 26 .4%) (32) . Findings of a study by Kocabaş et al. revealed that COPD patients continue to expose to risk factors and that their compliance to treatment is poor (33) . Additionally, the socioeconomic status such as income, education, occupationcould also be associated with adherence to treatment among asthma/ COPD patients. As, the majority of our patients had low education level, the possible impact of the patients' socioeconomic status on their compliance to treatment and adherence to visits should be investigated further.
In our analysis, the disease control level of the asthma patients with high compliance to treatment markedly improved during the follow-up. Among those with high compliance, the percentage of patients with total control increased from 44% at visit-2 to 63% at visit-3. Among those with high compliance, the percentage of patients with uncontrolled disease was only 5% in all three visits. Similarly, among COPD patients with high compliance, the percentage of those in GOLD stage A disease severity increased from 41% to 54% between visit-1 and visit-2. On the other hand, the patient's individual perception of the disease severity makes the interpretation of these data complicated. That is, a patient who does not feel well may become either more compliant to treatment to feel better or less compliant thinking that the medication is ineffective. This issue is one of the limitations of our study. As the patients' adherence to visits during 1-year of follow-up is poor in our population, the parameters including medication adherence, medication efficiency and disease prognosis could not be evaluated in patients with poor adherence to visits. However, this limitation is an expected consequence of the real world studies.
This study presents the data of a non-interventional, real world observations and it is the first study that is conducted on newly diagnosed, treatment-naïve asthma/COPD patients in Turkey. The major limitation of the study is that the follow-up of patients was not regular due to the study design. Yet, we suggest that the education programs for general public, especially in a school or occupational setting, about asthma/COPD are required to enable members of the public to recognise disease symptoms and their consequences and encourage those with asthma/COPD to seek medical attention and follow their disease management program. In addition to implementing targeted campaigns to raise public awareness of the disease and early symptoms, it is also necessary to design educational interventions for patients to increase their understanding of the disease, and improve selfmanagement. Education programs can be delivered individually or in group sessions, either through faceto-face contact or remote communication via telephone or email.
In conclusion, improving the awareness and adherence to guidelines to help in early diagnosis, and also adherence to follow-up visits which include checking adherence/compliance to the medication plan may be the key of better health outcomes in patients with asthma/COPD.
